• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Hyperion DeFi Inc.

    7/22/25 11:20:31 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYPD alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001563422
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    HYPERION DEFI, INC.
    SEC File Number
    001-38365
    Address of Issuer
    23461 SOUTH POINTE DRIVE,
    SUITE 390
    LAGUNA HILLS
    CALIFORNIA
    92653
    Phone
    833-393-6684
    Name of Person for Whose Account the Securities are To Be Sold
    MATHER CHARLES E IV
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    245 Summer Street
    Boston � MA � 02110
    136217515.00288280807/22/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/18/2018Open Mkt PurchasePublic MarketCheckbox not checked1209/18/2018Open market
    Common09/19/2018Open Mkt PurchasePublic MarketCheckbox not checked3709/19/2018Public Market
    Common05/28/2021Open Mkt PurchasePublic MarketCheckbox not checked3705/28/2021Open market
    Common11/01/2021Open Mkt PurchasePublic MarketCheckbox not checked4911/01/2021Open Market
    Common03/31/2022Open Mkt PurchasePublic MarketCheckbox not checked4903/31/2022Open Market
    Common05/18/2022Open Mkt PurchasePublic MarektCheckbox not checked8705/18/2022Open Market
    Common05/15/2023Open Mkt PurchasePublic MarketCheckbox not checked4905/15/2023Open Market
    Common05/26/2023Open Mkt PurchasePublic MarketCheckbox not checked3705/26/2023Open market
    Common06/17/2025Stock AwardIssuerCheckbox not checked100006/17/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    07/22/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Heather Foxworth as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for MATHER CHARLES E IV

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $HYPD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HYPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Jung Hyunsu was granted 1,000,000 shares, increasing direct ownership by 200% to 1,500,000 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    8/20/25 4:49:06 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jacobson Rachel was granted 50,000 shares, increasing direct ownership by 794% to 56,301 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    8/20/25 4:48:05 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R was granted 50,000 shares, increasing direct ownership by 746% to 56,706 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    8/20/25 4:47:10 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corporate Crypto Treasury Surge Accelerates as Bitcoin Hits Fresh Institutional Milestone

    Equity Insider News CommentaryIssued on behalf of CEA Industries, Inc. VANCOUVER, BC, Sept. 5, 2025 /PRNewswire/ -- Equity Insider News Commentary – BlackRock's Bitcoin ETF inflows recently surged to $289.8 million (on Sept. 4)[1], marking another record day for institutional adoption despite August's $751 million ETF outflows that preceded this dramatic reversal[2]. Meanwhile, U.S. Bank resumed Bitcoin custody services on September 3[3], reflecting growing institutional demand as major financial institutions pivot toward digital asset infrastructure. This momentum positions publicly traded cryptocurrency companies to capture significant value as corporate America accelerates its digital ass

    9/5/25 10:55:00 AM ET
    $BITF
    $BNC
    $COIN
    Finance: Consumer Services
    Finance
    Industrial Machinery/Components
    Industrials

    Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    Successfully establishes cryptocurrency treasury reserve focused on the HYPE token and becomes the first publicly listed U.S. company to implement DeFi strategies on Hyperliquid blockchain Accumulates more than 1.5 million HYPE to date and establishes co-branded validator with Kinetiq Reiterates FDA registration of the Optejet User Filled Device (UFD) remains on track for September 2025 LAGUNA HILLS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD), the first publicly-listed U.S. company to implement DeFi strategies on its treasury of HYPE, the native token of the Hyperliquid protocol, and a pioneer in ophthalmic digital technologies, today provided a corpora

    8/13/25 4:01:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi. To access the Ca

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Financials

    Live finance-specific insights

    View All

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi. To access the Ca

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    SEC Filings

    View All

    Hyperion DeFi Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    8/20/25 6:20:11 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Hyperion DeFi Inc.

    S-8 - HYPERION DEFI, INC. (0001682639) (Filer)

    8/18/25 5:15:08 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    8/13/25 4:15:30 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care